The new title, ''Non-ST-Elevation Acute Coronary Syndromes (NSTE-ACS),'' for this full revision of the 2007 American College of Cardiology Foundation/American Heart Association guideline titled ''Unstable Angina/Non-ST-Elevation Myocardial Infarction,'' more concisely emphasizes the continuum between unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI). They can be indistinguishable at presentation and therefore are considered together using the terminology non-STelevation acute coronary syndromes. Approximately 70% of patients with an acute coronary syndrome have an NSTE-ACS, comprising more than 625 000 patients annually. 1 In the appropriate clinical context, if cardiac biomarkers are normal, the patient is deemed to have UA; if troponins are elevated, the patient is considered to have an NSTEMI. 2 Additional new terminology relates to the initial strategy for management of patients with NSTE-ACS. The initial treatment pathways have been recategorized into, as previously, an early invasive strategy, seeking to rapidly risk stratify patients by angiographic assessment of their coronary anatomy with intent to perform revascularization when appropriate. The new designation, an ischemia-guided strategy, has replaced the previous term, initial conservative therapy, to more clearly convey the physiologic rationale of this approach. Ischemia-guided strategy involves guideline-directed medical therapy, with coronary angiography only if the patient experiences refractory or recurrent ischemic symptoms or develops hemodynamic instability.
Finally, this guideline highlights the third universal definition of myocardial infarction, 3 which differentiates myocardial infarction caused by a primary coronary artery process, such as spontaneous plaque rupture, from a myocardial infarction related to reduced myocardial oxygen supply and/or increased demand in the absence of a direct coronary artery process.
Patients with chest pain or other symptoms suggesting acute coronary syndromes (ACS) should have
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12-lead electrocardiography (ECG) performed and evaluated within 10 minutes of arrival at an emergency facility, and serial ECGs performed to detect ischemic changes. Serial cardiac troponin I or T levels (using a contemporary assay) should be obtained at presentation and at 3 to 6 hours after symptom onset. Risk scores can help assess prognosis. In patients with symptoms consistent with ACS without objective evidence of myocardial ischemia (nonischemic ECG and normal cardiac troponin levels), noninvasive imaging is reasonable before emergency department discharge or within 72 hours after discharge. 2. Standard initial medical therapies include: supplemental oxygen for arterial oxygen saturation <90% or respiratory distress; sublingual nitroglycerin; oral β-blocker therapy within the first 24 hours in the absence of heart failure, low output state, increased risk for cardiogenic shock or other contraindications to β blockade; nondihydropyridine calcium channel blocker for continuing or recurrent ischemia and contraindication to β blockade (in the absence of clinically significant left ventricular dysfunction). Nonsteroidal anti-inflammatory drugs (except aspirin) should not be initiated and should be discontinued during the hospitalization for NSTE-ACS because of the increased risk of major adverse cardiac events associated with their use.
Initial antiplatelet/anticoagulant therapy includes:
325-mg chewable aspirin at presentation, followed by a daily maintenance dose of aspirin at 81 to 126 mg daily. A P2Y 12 inhibitor (clopidogrel or ticagrelor) in addition to aspirin for up to 12 months in patients treated with either an early-invasive or ischemiaguided strategy. In addition to antiplatelet therapy, parenteral anticoagulation is indicated with enoxaparin, bivalirudin, fondaparinux, or unfractionated heparin.
A high-intensity statin should be initiated or continued
in all patients without contraindications. Angiotensinconverting enzyme inhibitors should be started and continued indefinitely with a left ventricular ejection fraction ≤40%, or hypertension, diabetes, or stable chronic kidney disease unless contraindicated.
NSTE-ACS: Definite or Likely
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Initiate DAPT and Anticoagulant Therapy 5. An algorithm (Figure 1 ) details the components of an early invasive strategy or an ischemia-guided strategy. An early invasive strategy is indicated for patients with refractory angina or hemodynamic or electrical instability and those at elevated risk for clinical events. An early invasive strategy is not recommended for patients with extensive comorbidities (eg, hepatic, renal, or pulmonary failure; cancer) in whom the risks of revascularization and comorbid conditions are likely to outweigh the benefits of revascularization. An ischemia-guided strategy is appropriate for low-risk score patients (Thrombolysis In Myocardial Infarction or Global Registry of Acute Coronary Events), low-risk troponin-negative women, and by patient or clinician preference in the absence of high-risk features. When an ischemiaguided strategy is chosen, noninvasive stress testing is recommended prior to hospital discharge to detect severe ischemia occurring at a low-stress threshold. Despite landmark advances in the care of patients with NSTE-ACS, emerging diagnostic and therapeutic strategies have posed new challenges. Evidence-based decisions will require comparative effectiveness studies of available and novel potent antiplatelet agents that are indicated, in addition to anticoagulant therapy irrespective of the initial treatment strategy. The paradox of newer and more potent antithrombotic and anticoagulant drugs that reduce major adverse cardiac outcomes but increase bleeding risk occurs with the greatest frequency in patients with atrial fibrillation. Atrial fibrillation patients who develop NSTE-ACS and receive a coronary stent are the population at risk from triple anticoagulant/antiplatelet therapy. The optimal regimen requires ascertainment.
The use of cardiac troponin, the preferred biomarker of myocardial necrosis, is rapidly evolving. Although a truly high-sensitive cardiac troponin is not currently available in the United States, the sensitivity of contemporary assays continues to increase, accompanied by higher rates of elevated cardiac troponin unrelated to coronary plaque rupture. This diagnostic quandary necessitates investigation, potentially addressing measurement of absolute cardiac troponin change rather than traditional analysis of relative alterations.
More than half of the NSTE-ACS mortality occurs in older patients, with this high-risk cohort increasing as our population ages. An unmet need is to more clearly distinguish their optimal management strategies. An appreciable number of NSTE-ACS patients have angiographically normal or nonobstructive coronary artery disease; women predominate in this population and their prognosis is not benign. Clinical advances are predicated on clarification of the pathophysiology of this challenging syndrome.
A fundamental aspect of all clinical practice guidelines is that these evidence-based documents cannot encompass all clinical circumstances, nor can they replace the judgment of individual physicians in the management of each patient. The science of medicine is rooted in evidence and the art of medicine is based on the application of this evidence to the individual NSTE-ACS patient.
